Atara Biotherapeutics, Inc.
ATRADrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How ATRA's past catalysts played out
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
EBV-induced Lymphomas
EBV-specific T cells (EBV-CTLs)
EBV-induced Lymphomas
CMV-pp65 CTLs
Cytomegalovirus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
EBV-specific T cells (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
CMV-pp65 CTLs | Phase 2 | Cytomegalovirus | - | - |
Frequently asked questions
What is in Atara Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Atara Biotherapeutics, Inc.'s (ATRA) pipeline across Phase 2. Its lead program is Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Atara Biotherapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Atara Biotherapeutics, Inc. (ATRA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATRA biotech catalysts?→
Add ATRA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Atara Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.